EGFR signaling pathway occupies an important position in cancer‐related downstream signaling pathways of Pyk2

The Human Ion Channel TRPM2 Modulates Neuroblastoma Cell Survival and Mitochondrial Function through Pyk2, CREB, and MCU Activation

(2018) Iwona Hirschler-Laszkiewicz et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells

(2017) Alessandro Genna et al.   JOURNAL OF CELL BIOLOGY

CCL18-dependent translocation of AMAP1 is critical for epithelial to mesenchymal transition in breast cancer

(2017) Haiyan Li et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production

(2017) Xinfang Yu et al.   MOLECULAR CARCINOGENESIS

E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells

(2017) T Kato et al.   ONCOGENE

Chemotherapy-Induced Ca 2+ Release Stimulates Breast Cancer Stem Cell Enrichment

(2017) Haiquan Lu et al.   Cell Reports

Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis

(2016) Nandini Verma et al.   CANCER RESEARCH

PYK2 via S6K1 regulates the function of androgen receptors and the growth of prostate cancer cells

(2016) Yu-Hsuan Hsiao et al.   ENDOCRINE-RELATED CANCER

Activation of focal adhesion kinase through an interaction with β4 integrin contributes to tumorigenicity of colon cancer

(2016) Yu-Ling Tai et al.   FEBS LETTERS

Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer

(2016) Go Omura et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Epidermal growth factor receptor expression in carcinoma gallbladder: A prospective study in Indian scenario

(2016) Nikhilesh Kumar et al.   Journal of Cancer Research and Therapeutics

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling

(2016) Denis Lane et al.   Molecular Cancer

Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors

(2016) Timothy A. Marlowe et al.   MOLECULAR CANCER THERAPEUTICS

Understanding the CREB1-miRNA feedback loop in human malignancies

(2016) Ya-Wen Wang et al.   TUMOR BIOLOGY

The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma

(2016) Yusuke Kamihara et al.   Oncotarget

Quantitative phosphoproteomics reveals the protein tyrosine kinase Pyk2 as a central effector of olfactory receptor signaling in prostate cancer cells

(2015) Heike Wiese et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers

(2015) A Harlé et al.   BRITISH JOURNAL OF CANCER

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15

(2015) Vita Golubovskaya et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma

(2015) M B Meads et al.   ONCOGENE

The role of Pyk2 in the CCR7-mediated regulation of metastasis and viability in squamous cell carcinoma of the head and neck cells in vivo and in vitro

(2015) YANG YUE et al.   ONCOLOGY REPORTS

Expression and clinical significance of focal adhesion kinase and adrenomedullin in epithelial ovarian cancer

(2015) MINGQUN LI et al.   Oncology Letters

PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition

(2015) Nandini Verma et al.   Nature Communications

Pyk2 promotes tumor progression in multiple myeloma

(2014) Y. Zhang et al.   BLOOD

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2014) S. Misale et al.   Science Translational Medicine

CCR7 Regulates Cell Migration and Invasion through JAK2/STAT3 in Metastatic Squamous Cell Carcinoma of the Head and Neck

(2014) Fa-Yu Liu et al.   Biomed Research International

Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients’ overall survival

(2013) B-H Kuang et al.   BRITISH JOURNAL OF CANCER

High Expression of Proline-Rich Tyrosine Kinase2 is Associated with Poor Survival of Hepatocellular Carcinoma via Regulating Phosphatidylinositol 3-Kinase/AKT Pathway

(2012) Jie Cao et al.   ANNALS OF SURGICAL ONCOLOGY

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

(2012) H. Gan et al.   EUROPEAN JOURNAL OF CANCER

Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer

(2012) Hong-Fei Ji et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors

(2012) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells

(2012) Marco Genua et al.   PLoS One

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

How focal adhesion kinase achieves regulation by linking ligand binding, localization and action

(2011) Stefan T Arold   CURRENT OPINION IN STRUCTURAL BIOLOGY

Compensatory Function of Pyk2 Protein in the Promotion of Focal Adhesion Kinase (FAK)-null Mammary Cancer Stem Cell Tumorigenicity and Metastatic Activity

(2011) Huaping Fan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Proline-Rich Tyrosine Kinase 2 (Pyk2) Promotes Cell Motility of Hepatocellular Carcinoma through Induction of Epithelial to Mesenchymal Transition

(2011) Chris K. Sun et al.   PLoS One

The Role of Proline Rich Tyrosine Kinase 2 (Pyk2) on Cisplatin Resistance in Hepatocellular Carcinoma

(2011) Wei Geng et al.   PLoS One

Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer

(2010) Cha Kyong Yom et al.   BREAST CANCER RESEARCH AND TREATMENT

Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model

(2010) Cedo M Bagi et al.   CANCER BIOLOGY & THERAPY

Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions

(2010) M. D. Schaller   JOURNAL OF CELL SCIENCE

TROY (TNFRSF19) Is Overexpressed in Advanced Glial Tumors and Promotes Glioblastoma Cell Invasion via Pyk2-Rac1 Signaling

(2010) V. M. Paulino et al.   MOLECULAR CANCER RESEARCH

Proline-rich tyrosine kinase-2 is critical for CD8 T-cell short-lived effector fate

(2010) S. Beinke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2) with osteogenic activity in osteoblast cells

(2009) John G. Allen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism

(2009) Maria Grazia Cattaneo et al.   EXPERIMENTAL CELL RESEARCH

Targeting Pyk2 for therapeutic intervention

(2009) Christopher A Lipinski et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design

(2009) Seungil Han et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Biomarkers for epithelial-mesenchymal transitions

(2009) Michael Zeisberg et al.   JOURNAL OF CLINICAL INVESTIGATION

The Pyk2 FERM domain as a target to inhibit glioma migration

(2009) J. C. Loftus et al.   MOLECULAR CANCER THERAPEUTICS

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

Focal Adhesion Kinase-Related Proline-Rich Tyrosine Kinase 2 and Focal Adhesion Kinase Are Co-Overexpressed in Early-Stage and Invasive ErbB-2-Positive Breast Cancer and Cooperate for Breast Cancer Cell Tumorigenesis and Invasiveness

(2008) Emy Behmoaram et al.   AMERICAN JOURNAL OF PATHOLOGY

Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors

(2008) Cedo M. Bagi et al.   CANCER

RhoC Promotes Metastasis via Activation of the Pyk2 Pathway in Prostate Cancer

(2008) M. Iiizumi et al.   CANCER RESEARCH

Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation

(2008) C. K. Sun et al.   CARCINOGENESIS

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family

(2008) H. Michael Shepard et al.   JOURNAL OF CLINICAL INVESTIGATION

Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer

(2008) Siyang Zhang et al.   LUNG CANCER

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

(2008) A. Vultur et al.   MOLECULAR CANCER THERAPEUTICS

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE